5-Iminodaunorubicin. Reduced Cardiotoxic Properties in an Antitumor Anthracycline

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 1979 Jan 1

PMID 423181

Citations 5

Authors

G L Tong

D W Henry

E M ACTON

Affiliations

Soon will be listed here.

Abstract

Treatment of daunorubicin with methanolic ammonia affords 5-iminodaunorubicin, the first quinone-modified analogue of either daunorubicin or adriamycin. This product retains antileukemic activity in mice, is less cardiotoxic by electrocardiographic measurements in rats, and is nonmutagenic in Salmonella typhimurium (Ames test).

Citing Articles

Effects of 5-iminodaunorubicin on nucleoli of rats.

Peters J, Evans M, Jensen R, ACTON E Cancer Chemother Pharmacol. 1980; 4(4):263-6.

PMID: 7438328 DOI: 10.1007/BF00255271.

Prevention of adriamycin toxicity.

Banks A, Jones T, Koch T, Friedman R, Bachur N Cancer Chemother Pharmacol. 1983; 11(2):91-3.

PMID: 6627601 DOI: 10.1007/BF00254252.

Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Bouma J, Beijnen J, Bult A, Underberg W Pharm Weekbl Sci. 1986; 8(2):109-33.

PMID: 3520474 DOI: 10.1007/BF02086146.

The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Graham M, Newell D, Foster B, Calvert A Cancer Chemother Pharmacol. 1989; 23(1):8-14.

PMID: 2909292 DOI: 10.1007/BF00258450.

Comparative effects of doxorubicin and 4'-epi-doxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line.

Cantoni O, Sestili P, Cattabeni F, Geroni C, Giuliani F Cancer Chemother Pharmacol. 1990; 27(1):47-51.

PMID: 1700932 DOI: 10.1007/BF00689275.